Atrophic gastritis c3 indicates that the patient has a large area of atrophic gastritis, close to the cardia position, which is moderate atrophy. However, this disease can be survived for a long time through active treatment and usually does not affect the patient’s life expectancy. If not treated in time, there may be a risk of cancer, which may affect the patient’s life expectancy. Atrophic gastritis is a chronic disease of the digestive system caused by Helicobacter pylori infection, duodenogastric reflux, autoimmune factors, etc. Atrophic gastritis c3 indicates that the site of atrophy is close to the cardia position, and the scope of atrophy is large, which is moderate atrophy. Atrophic gastritis c3 patients through a combination of general treatment (such as smoking and alcohol cessation, light diet, etc.), drug therapy (such as eradication of Helicobacter pylori infection drugs, immunosuppressants, gastric mucosal protectants, etc.), Chinese patent medicine treatment (such as Morodan, gastric Fuchun, etc.) and other integrated treatment, treatment, usually a better prognosis, and will not affect the life expectancy of patients. However, if patients do not receive timely treatment, the condition may aggravate, thus risking cancerous transformation, jeopardizing patients’ lives and affecting their survival time. It is recommended that patients go to the hospital in time and follow the doctor’s instructions to standardize the treatment.
Support Us
Discussion
Share your experience, or seek help from fellow patients.
